为透析患者开处方。
Prescribing for patients on dialysis.
作者信息
Smyth Brendan, Jones Ceridwen, Saunders John
机构信息
Royal Prince Alfred Hospital, Sydney.
出版信息
Aust Prescr. 2016 Feb;39(1):21-4. doi: 10.18773/austprescr.2016.008. Epub 2016 Feb 1.
Abstract
The pharmacokinetics of a drug may be altered in patients with renal impairment who require dialysis. Some drugs are contraindicated. The drug's clearance and therapeutic index determine if a dose adjustment is needed. A lower dose or less frequent dosing may be required. Consult a reference source or the patient's nephrologist before prescribing. Start at a low dose and increase gradually. If possible give once-daily drugs after dialysis.
摘要
对于需要透析的肾功能损害患者，药物的药代动力学可能会发生改变。某些药物是禁忌的。药物的清除率和治疗指数决定是否需要调整剂量。可能需要较低的剂量或减少给药频率。在开处方前查阅参考资料或咨询患者的肾病科医生。从低剂量开始并逐渐增加。如果可能的话，在透析后给予每日一次的药物。
相似文献
1
Prescribing for patients on dialysis.
Aust Prescr. 2016 Feb;39(1):21-4. doi: 10.18773/austprescr.2016.008. Epub 2016 Feb 1.
2
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Thromb Haemost. 2015 Apr;113(4):719-27. doi: 10.1160/TH14-06-0547. Epub 2015 Jan 8.
3
Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.
Clin Pharmacokinet. 2006;45(11):1115-24. doi: 10.2165/00003088-200645110-00005.
4
Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
J Clin Pharmacol. 2012 Jan;52(1 Suppl):79S-90S. doi: 10.1177/0091270011415410.
5
Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?
Intern Med J. 2014 Jan;44(1):77-85. doi: 10.1111/imj.12291.
6
[Dosage of drugs in patients with kidney diseases].
Wiad Lek. 1996;49(7-12):87-91.
7
Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Nephrol Dial Transplant. 2003 Feb;18(2):362-9. doi: 10.1093/ndt/18.2.362.
8
Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
HIV Clin Trials. 2013 May-Jun;14(3):99-109. doi: 10.1310/hct1403-99.
9
The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Br J Clin Pharmacol. 2000;49 Suppl 1(Suppl 1):27S-33S. doi: 10.1046/j.1365-2125.2000.00150.x.
10
Appendix to dialysis centre guidelines: recommendations for the relationship between outpatient haemodialysis centres and reference hospitals. Opinions from the Outpatient Dialysis Group. Grupo de Trabajo de Hemodiálisis Extrahospitalaria.
Nefrologia. 2011;31(6):664-9. doi: 10.3265/Nefrologia.pre2011.Oct.11001.
引用本文的文献
1
Changes in Protein Expression of Renal Drug Transporters and Drug-Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients.
Clin Pharmacol Ther. 2025 Sep;118(3):682-692. doi: 10.1002/cpt.3715. Epub 2025 May 15.
2
Treatment of insomnia, restless legs, cramps, and pain associated with chronic kidney disease: results from a multinational survey of kidney supportive care practice.
BMC Nephrol. 2025 Apr 23;26(1):204. doi: 10.1186/s12882-025-04107-1.
3
Evaluation of Dose Adjustment in Patients With Renal Impairment at Muhimbili National Hospital in Tanzania.
Hosp Pharm. 2024 Feb;59(1):86-93. doi: 10.1177/00185787231188921. Epub 2023 Aug 1.
4
Prescribing and peritoneal dialysis.
Aust Prescr. 2023 Jun;46(1):5-8. doi: 10.18773/austprescr.2023.001.
5
Collapsing focal segmental glomerulosclerosis secondary to COVID-19: A systematic review and meta-analysis.
Ann Med Surg (Lond). 2023 Feb 7;85(2):92-101. doi: 10.1097/MS9.0000000000000107. eCollection 2023 Feb.
6
Antibiotics utilization patterns and dosage appropriateness among patients receiving hemodialysis.
Saudi Pharm J. 2022 Jul;30(7):971-978. doi: 10.1016/j.jsps.2022.05.005. Epub 2022 May 23.
7
Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
Clin Mol Hepatol. 2020 Oct;26(4):554-561. doi: 10.3350/cmh.2020.0058. Epub 2020 Aug 28.
8
When ESKD complicates the management of pain.
Semin Dial. 2020 May;33(3):286-296. doi: 10.1111/sdi.12881. Epub 2020 May 4.
9
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety.
Clin Pharmacol Drug Dev. 2019 Apr;8(3):281-289. doi: 10.1002/cpdd.650. Epub 2019 Jan 24.
10
Trends in Opioid Prescribing Among Hemodialysis Patients, 2007-2014.
Am J Nephrol. 2019;49(1):20-31. doi: 10.1159/000495353. Epub 2018 Dec 13.
本文引用的文献
1
Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women.
CMAJ. 2015 Jun 16;187(9):648-656. doi: 10.1503/cmaj.150067. Epub 2015 Apr 27.
2
SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.
Australas Med J. 2014 Oct 31;7(10):405-15. doi: 10.4066/AMJ.2014.2181. eCollection 2014.
3
Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation.
Nephrol Dial Transplant. 2015 Mar;30(3):491-8. doi: 10.1093/ndt/gfu334. Epub 2014 Oct 28.
4
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Intern Med J. 2014 Jun;44(6):525-36. doi: 10.1111/imj.12448.
5
Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease.
Curr Opin Nephrol Hypertens. 2014 May;23(3):306-13. doi: 10.1097/01.mnh.0000444912.40418.45.
6
Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care.
Eur J Clin Pharmacol. 2013 Sep;69(9):1701-7. doi: 10.1007/s00228-013-1520-x. Epub 2013 May 10.
7
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Nat Rev Nephrol. 2013 Mar;9(3):147-53. doi: 10.1038/nrneph.2013.12. Epub 2013 Jan 29.
8
Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study.
Nephrology (Carlton). 2012 Nov;17(8):710-7. doi: 10.1111/j.1440-1797.2012.01655.x.
9
The prevalence of peripheral neuropathy in hemodialysis patients.
Clin Nephrol. 2012 Jun;77(6):468-75. doi: 10.5414/cn107188.
10
Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients.
J Opioid Manag. 2008 Nov-Dec;4(6):335-6, 339-44.
Zotero 插件